Harrow (HROW) Operating Income (2010 - 2026)
Harrow's (HROW) quarterly Operating Income came in at -$22.1 million in Q1 2026, down 96.58% year-on-year from -$645.8 million in Q1 2025, and down 241.62% quarter-over-quarter from $15.6 million in Q4 2025.
Harrow (HROW) Operating Income (2010 - 2026) Analysis & Trends
Harrow's Operating Income history runs 17 years deep, the most recent figure standing at -$22.1 million for Q1 2026.
- On a quarterly basis, Operating Income fell 96.58% year-over-year to -$22.1 million in Q1 2026; TTM through Mar 2026 was $19.7 million, a 335.3% increase from a year earlier, with the FY2025 full-year figure at $30.5 million, up 245.9% from the prior year.
- Operating Income retreated to -$22.1 million in Q1 2026 per HROW's latest filing, from $15.6 million in the prior quarter.
- Across five years, Operating Income topped out at $15.6 million in Q4 2025 and bottomed at -$22.1 million in Q1 2026.
- The 5-year median for Operating Income is $1.5 million (2024), against an average of $1.2 million.
- Across the five-year window, Operating Income jumped 1955.32% in 2023 and slumped 672.56% in 2024, its largest moves.
- Year by year, Operating Income stood at -$1.8 million in 2022, then tumbled by 174.18% to -$4.9 million in 2023, then surged by 364.59% to $12.9 million in 2024, then increased by 20.87% to $15.6 million in 2025, then sank by 241.62% to -$22.1 million in 2026.
- Per Business Quant, the three latest HROW Operating Income figures stand at -$22.1 million (Q1 2026), $15.6 million (Q4 2025), and $14.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 325.80 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | -22.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.08 Mn |
| Dec 31, 2025 | 15.59 Mn |
| Sep 30, 2025 | 14.75 Mn |
| Jun 30, 2025 | 11.41 Mn |
| Mar 31, 2025 | -11.23 Mn |
| Dec 31, 2024 | 12.90 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.53 Mn |
| Mar 31, 2024 | -6.93 Mn |
| Dec 31, 2023 | -4.88 Mn |
| Sep 30, 2023 | 1.74 Mn |
| Jun 30, 2023 | 2.35 Mn |
| Mar 31, 2023 | 1.21 Mn |
| Dec 31, 2022 | -1.78 Mn |
| Sep 30, 2022 | -94,000.00 |
| Jun 30, 2022 | 1.69 Mn |
| Mar 31, 2022 | 2.10 Mn |
| Dec 31, 2021 | -1.76 Mn |
| Sep 30, 2021 | -3.72 Mn |
| Jun 30, 2021 | 4.17 Mn |